Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Research & Development (2021 - 2025)

Historic Research & Development for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to $44.0 million.

  • Prime Medicine's Research & Development rose 904.81% to $44.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $160.0 million, marking a year-over-year decrease of 160.66%. This contributed to the annual value of $155.3 million for FY2024, which is 499.24% up from last year.
  • Latest data reveals that Prime Medicine reported Research & Development of $44.0 million as of Q3 2025, which was up 904.81% from $41.4 million recorded in Q2 2025.
  • In the past 5 years, Prime Medicine's Research & Development ranged from a high of $52.9 million in Q4 2021 and a low of $7.4 million during Q3 2021
  • For the 5-year period, Prime Medicine's Research & Development averaged around $33.9 million, with its median value being $37.8 million (2024).
  • The largest annual percentage gain for Prime Medicine's Research & Development in the last 5 years was 23847.3% (2022), contrasted with its biggest fall of 4505.28% (2022).
  • Prime Medicine's Research & Development (Quarter) stood at $52.9 million in 2021, then plummeted by 45.05% to $29.1 million in 2022, then skyrocketed by 42.66% to $41.5 million in 2023, then fell by 17.74% to $34.1 million in 2024, then increased by 28.99% to $44.0 million in 2025.
  • Its last three reported values are $44.0 million in Q3 2025, $41.4 million for Q2 2025, and $40.6 million during Q1 2025.